ArticleTherapeutics and clinical risk management2012
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.
Article in Therapeutics and clinical risk management, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study
Novel Treatment of Some Men With Non-Obstructive Azoospermia (NT-NOA): A Clinical Interventional Study
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Effectiveness of fracture liaison service in reducing the risk of secondary fragility fractures in adults aged 50 and older: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Pooled it
- Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity.Cell reports. Medicine · 2024Trial
- Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.Arthritis research & therapy · 2022Trial
- Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation.Scientific reports · 2025Article
- Cinobufotalin prevents bone loss induced by ovariectomy in mice through the BMPs/SMAD and Wnt/β-catenin signaling pathways.Animal models and experimental medicine · 2024Article
- Hypocalcemia in Patients With Osteoporosis and Normal Renal Function, Treated With Denosumab, a Retrospective Analysis.Nutrition and metabolic insights · 2024Article
- Nonspecificity fingerprints for clinical-stage antibodies in solution.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Biologics: Teriparatide and Newer Anabolics.Indian journal of orthopaedics · 2023Review
- Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review.Translational pediatrics · 2023Review
- Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Article
- Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.Journal of bone and mineral metabolism · 2021Article
- Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden.Journal of dental research · 2021Article
- RANKL regulates male reproductive function.Nature communications · 2021Article
- Molecular Mechanisms and Emerging Therapeutics for Osteoporosis.International journal of molecular sciences · 2020Review
- A Novel Peptide, CK2.3, Improved Bone Formation in Ovariectomized Sprague Dawley Rats.International journal of molecular sciences · 2020Article
- Article
- Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases.Pharmacy (Basel, Switzerland) · 2020Article
- Polyphyllin VII attenuated RANKL-induced osteoclast differentiation via inhibiting of TRAF6/c-Src/PI3K pathway and ROS production.BMC musculoskeletal disorders · 2020Article
- Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.Frontiers in cell and developmental biology · 2020Review
- Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.Journal of bone and mineral metabolism · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis. Denosumab treatment is associated with a rapid, sustained, and reversible reduction in bone turnover markers, a continuous marked increase in bone mineral density at all sites, and a marked decrease in the risk of vertebral, hip, and nonvertebral fractures in women with postmenopausal osteoporosis. Therefore, it could be considered as an effective alternative to previous bisphosphonate treatment as well as first-line treatment of severe osteoporosis. Cost-effectiveness studies support this suggestion. In addition, denosumab seems to be the safest treatment option in patients with impaired renal function. Denosumab is characterized by reversibility of its effect after treatment discontinuation, in contrast with bisphosphonates. Large-scale clinical trials, including the extension of FREEDOM trial for up to 5 years, are reassuring for its safety. However, given its brief post-market period, vigilance regarding adverse events related to putative RANKL inhibition in tissues other than bone, as well as those related to bone turnover oversuppression, is advised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.